We have closed a third-party allotment of approximately 310 million yen to the Beyond Next Ventures No. 2 Investment Limited Partnership, Ono Venture Investment, Inc. Asahi Kasei Pharma Co., Ltd. and Gemseki Investment Limited Partnership. (Investor names are in no particular order, the same applies below) Ongoing, we will further accelerate the drug discovery business […]
Curreio, Inc. and Preferred Networks, Inc. announced they will start joint research on drug discovery using deep learning and structural analysis in April. Both companies will combine structural analysis technology using Curreio’s Cryo-EM and molecular design technology based on deep learning of PFN to speed up and improve the acc uracy of conventional structure-based drug […]
Curreio, Inc. and Keio University Institute for Advanced Biosciences have signed a joint research agreement with the aim of rapidly search for new physiologically active substances that can be used for drug discovery candidates. In recent years, the depletion of effective antibiotics due to the emergence of multidrug-resistant bacteria has become a serious problem all […]
We are pleased to inform that we have signed a memorandum for joint research with Veneno Technologies Co. Ltd., which has the technology for creating a library of disulfide-rich peptide (DRP), which is the next-generation drug discovery base molecule, and the state-of-the-art DRP screening technology PERISS ™. It is said that drug discovery is difficult […]
Curreio, Inc. has announced a strategic partnership with PeptiDream, Inc., which has a drug discovery development platform system: PDPS (Peptide Discovery Platform System). Structural analysis technology using Cryo-EM is one of the best technologies in the three-dimensional structural analysis of biomolecules, and was awarded the Nobel Prize in Chemistry in 2017. In particular, single particle […]
Curreio, Inc., which conducts structure-based drug discovery specialized in Cryo-EM, analyzes the structural information of the complex of the target protein and DNA aptamer, with the aim of searching for therapeutic drug candidate molecules for new coronavirus infections (hereinafter “COVID-19”). We are pleased to inform you that we have signed a joint research agreement with […]